stockrowAbCellera Biologics Inc. (ABCL) vs Arcutis Biotherapeutics, Inc. (ARQT)
- AbCellera Biologics Inc. ABCL 11.89 +6.83%
- Arcutis Biotherapeutics, Inc. ARQT 25.55 −5.37%
AbCellera Biologics Inc. and Arcutis Biotherapeutics, Inc. are both Biotechnology companies. AbCellera Biologics Inc. and Arcutis Biotherapeutics, Inc. are of similar size ($3.6B and $3.4B). AbCellera Biologics Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 119×. AbCellera Biologics Inc. grew revenue faster over the last twelve months: 101.3% against 60.0%. Arcutis Biotherapeutics, Inc. has the higher net margin (5.88% vs −248.8%) and the higher return on invested capital (23.5% vs −42.5%). Across the 17 metrics below, Arcutis Biotherapeutics, Inc. leads on 11 and AbCellera Biologics Inc. on 6.
Valuation
Profitability
| Metric | ABCL | ARQT | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 91.18% | 65.16% |
| Operating margin | (340.25%) | 6.91% | 0.00% |
| Net margin | (248.82%) | 5.88% | 0.00% |
| Free cash flow margin | (180.84%) | 11.74% | 0.00% |
| Return on equity | (17.30%) | 14.88% | (50.12%) |
| Return on assets | (12.15%) | 6.68% | (45.60%) |
| Return on invested capital | (42.52%) | 23.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack